Literature DB >> 10686026

Infection of five human liver cell lines by dengue-2 virus.

Y L Lin1, C C Liu, H Y Lei, T M Yeh, Y S Lin, R M Chen, H S Liu.   

Abstract

Elevated serum transaminase levels of dengue patients indicate the possible impact of dengue virus infection on liver function. To elucidate the action of dengue virus infection in liver cells, an in vitro cell line system was established that mimicked the liver status of diverse clinical patients. Briefly, four hepatoma cell lines (HA22T, Huh7, Hep3B, and PLC) and one nonmalignant hepatocyte cell line (Chang liver) were included, representing various levels of tumorigenicity and differentiation. Our data showed that in these five cell lines, dengue-2 virus attached to each cell type equally well; however, this virus had higher replication rates and levels of virion production in differentiated Huh7, PLC, Hep3B, and Chang liver cells. Likewise, a lower replication rate was observed in the de-differentiated HA22T cells. Differentiation-related factors seem to play an important role in dengue virus replication. Further study showed that sodium butyrate (NaB, a differentiation inducer) treatment enhanced dengue virus replication in HA22T cells. Moreover, we found that the severity of morphologic aberration and the increase in aspartate aminotransferase (AST) levels correlated with the virus replication rate in the four infected hepatoma cells. In conclusion, we showed that dengue virus can infect diverse liver cells with differing replication efficiency, which causes cytopathic effects (CPEs) of diverse severity. Among the CPEs, the increased AST levels correlated with the clinical results from 24 dengue fever patients, who showed increased AST levels at the onset of fever. In summary, we find that dengue-2 virus replicates actively and causes severe CPEs in differentiated hepatoma cells. Factors related to differentiation as well as tumorigenicity seem to play critical roles, though the mechanisms of action remain unclear. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10686026     DOI: 10.1002/(sici)1096-9071(200004)60:4<425::aid-jmv10>3.0.co;2-a

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  23 in total

1.  Chemical mutagenesis of dengue virus type 4 yields mutant viruses which are temperature sensitive in vero cells or human liver cells and attenuated in mice.

Authors:  J E Blaney; D H Johnson; C Y Firestone; C T Hanson; B R Murphy; S S Whitehead
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes.

Authors:  Szu-Yuan Pu; Ren-Huang Wu; Chi-Chen Yang; Tzu-Ming Jao; Ming-Han Tsai; Jing-Chyi Wang; Hui-Mei Lin; Yu-Sheng Chao; Andrew Yueh
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

3.  A potent prolyl tRNA synthetase inhibitor antagonizes Chikungunya and Dengue viruses.

Authors:  Jesse Hwang; Alfred Jiang; Erol Fikrig
Journal:  Antiviral Res       Date:  2018-12-03       Impact factor: 5.970

4.  Serotype-specific entry of dengue virus into liver cells: identification of the 37-kilodalton/67-kilodalton high-affinity laminin receptor as a dengue virus serotype 1 receptor.

Authors:  Chutima Thepparit; Duncan R Smith
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay.

Authors:  Chi-Chen Yang; Yi-Chen Hsieh; Shiow-Ju Lee; Szu-Huei Wu; Ching-Len Liao; Chang-Huei Tsao; Yu-Sheng Chao; Jyh-Haur Chern; Chung-Pu Wu; Andrew Yueh
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

6.  The secreted form of dengue virus nonstructural protein NS1 is endocytosed by hepatocytes and accumulates in late endosomes: implications for viral infectivity.

Authors:  Sophie Alcon-LePoder; Marie-Thérèse Drouet; Pascal Roux; Marie-Pascale Frenkiel; Michel Arborio; Anne-Marie Durand-Schneider; Michèle Maurice; Isabelle Le Blanc; Jean Gruenberg; Marie Flamand
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.

Authors:  Julie H McArthur; Anna P Durbin; Jennifer A Marron; Kimberli A Wanionek; Bhavin Thumar; Dennis J Pierro; Alexander C Schmidt; Joseph E Blaney; Brian R Murphy; Stephen S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2008-11       Impact factor: 2.345

8.  A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease.

Authors:  Chi-Chen Yang; Han-Shu Hu; Ren-Huang Wu; Szu-Huei Wu; Shiow-Ju Lee; Weir-Torn Jiaang; Jyh-Haur Chern; Zhi-Shun Huang; Huey-Nan Wu; Chung-Ming Chang; Andrew Yueh
Journal:  Antimicrob Agents Chemother       Date:  2013-10-21       Impact factor: 5.191

9.  Dengue virus (DV) replication in monocyte-derived macrophages is not affected by tumor necrosis factor alpha (TNF-alpha), and DV infection induces altered responsiveness to TNF-alpha stimulation.

Authors:  Satiya Wati; Peng Li; Christopher J Burrell; Jillian M Carr
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

10.  Models of dengue virus infection.

Authors:  Dennis A Bente; Rebeca Rico-Hesse
Journal:  Drug Discov Today Dis Models       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.